摘要
目的:分析痰热清注射液联合敏感抗菌药物治疗肺癌合并肺部感染的临床效果。方法:选取2022年1—12月监利市人民医院收治的肺癌合并肺部感染患者80例作为研究对象,随机分为对照组与观察组,各40例。对照组使用敏感抗菌药物治疗,观察组在对照组基础上使用痰热清注射液治疗。比较两组治疗效果。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.001)。治疗前,两组健康调查简表(SF-36)、卡氏功能状态评分量表评分比较,差异无统计学意义(P>0.05);治疗后,两组SF-36、卡氏功能状态评分量表评分高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组体温恢复正常时间、咳嗽消失时间、肺部干湿性啰音消失时间短于对照组,差异有统计学意义(P<0.001)。结论:痰热清注射液联合敏感抗菌药物治疗肺癌合并肺部感染的临床效果理想,能够改善患者症状,促进功能恢复,提高患者生活质量。
Objective:To analyze the clinical effect of Tanreqing injection with sensitive antibacterial drugs in the treatment of lung cancer with pulmonary infection.Methods:A total of 80 patients with lung cancer and pulmonary infection admitted to Jianli People's Hospital from January 2022 to December 2022 were selected as the study subjects.The patients were randomly divided into a control group and an observation group,with 40 in each group.The control group was treated with sensitive antibacterial drugs,while the observation group was treated with Tanreqing injection on the basis of the control group.The treatment effects in the two groups o were compared.Results:The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.001).Before treatment,there was no significant difference between the two groups in the scores of 36-Item Short Form Health Survey(SF-36)and Karnofsky performance status(P>0.05).After treatment,the scores of SF-36 and Karnofsky performance status in the two groups were higher than those before treatment,the scores in the ob-servation group were higher than those in the control group,and the difference was statistically significant(P<0.05).The time for re-turning to normal body temperature,the time for cough disappearance,and the time for dry and moist rales disappearance in the ob-servation group were shorter than those in the control group,and the differences were statistically significant(P<0.001).Conclusion:Tanreqing injection with sensitive antibacterial drugs has ideal clinical effects in the treatment of lung cancer with pulmonary infec-tion,and can ameliorate the symptoms of patients,promote the recovery of functions,and improve the patients'quality of life.
作者
贺思维
杨莲
He Siwei;Yang Lian(Department of Respiratory and Critical Care Medicine,Jianli People's Hospital,Jianli 433300,Hubei Province,China)
出处
《中国社区医师》
2024年第10期68-70,共3页
Chinese Community Doctors
关键词
痰热清
敏感抗菌药物
肺癌
肺部感染
Tanreqing
Sensitive antibacterial drugs
Lung cancer
Pulmonary infection